[{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Merus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Approved FDF","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Partner Therapeutics \/ Partner Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Partner Therapeutics \/ Partner Therapeutics"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Partner Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Granulocyte Colony Stimulating Factor","moa":"Granulocyte colony-stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ Partner Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Partner Therapeutics"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Nobelpharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Partner Therapeutics \/ Partner Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Partner Therapeutics \/ Partner Therapeutics"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Partner Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ Partner Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Partner Therapeutics \/ Partner Therapeutics"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ Partner Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Partner Therapeutics"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Partner Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Partner Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ University of Colorado","highestDevelopmentStatusID":"4","companyTruncated":"Partner Therapeutics \/ University of Colorado"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2 | HER3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Partner Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Partner Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
